Skip to main content
Midas Edge

AIM ImmunoTech Inc.

For the period ended Sep 30, 2026. Filed Sep 30, 2026.

View on SEC.gov

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

Sep 30, 2026 · Filed Sep 30, 2026

AIM$0.16+1.9%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

Notes:

(1)The NEOs voluntarily waived all 2024 and 2025 bonus compensation in support of the Company’s cash conservation efforts.
(2)As part of our cash conservation strategy, we issued common stock as a substitute for cash salaries to certain Named Executive Officers. For the year ended December 31, 2024, stock issued as payroll totaled $250,000, which is included in the overall equity-based compensation expense. There was no stock issued as payroll for the year ended December 31, 2025.
(3)The options for 2024 and 2025 were waived.
(4)Mr. Equels’ All Other Compensations consists of:
20242025
Life & Disability Insurance$41,073$41,073
Healthcare Insurance26,61930,998
Car Expenses/Allowance18,00018,000
401(k) Matching Funds20,70016,245
Total$106,392$106,316

Mr. Dickey’s All Other Compensations consists of:

20242025
Life & Disability Insurance$-$-
Healthcare Insurance--
Car Expenses/Allowance--
401(k) Matching Funds--
Total$-$-

Mr. Rodino’s All Other Compensations consists of:

20242025
Life & Disability Insurance$2,524$2,524
Healthcare Insurance25,39229,674
Car Expenses/Allowance14,40014,400
401(k) Matching Funds20,70018,750
Total$63,016$65,348
(5)Includes approximately $141,667 in salary that was voluntarily deferred by Mr. Equels due to Company cash flow concerns.
(6)Includes approximately $70,833 in salary that was voluntarily deferred by Mr. Rodino due to Company cash flow concerns.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.